Northern Trust Corp Has $37.81 Million Holdings in bluebird bio Inc (BLUE)

Northern Trust Corp lowered its position in bluebird bio Inc (NASDAQ:BLUE) by 59.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 240,936 shares of the biotechnology company’s stock after selling 351,262 shares during the period. Northern Trust Corp owned approximately 0.44% of bluebird bio worth $37,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Commonwealth Equity Services LLC lifted its stake in bluebird bio by 24.7% in the first quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 383 shares during the last quarter. CIBC Asset Management Inc increased its position in shares of bluebird bio by 28.5% during the second quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 395 shares during the period. Dynamic Technology Lab Private Ltd increased its position in shares of bluebird bio by 43.2% during the second quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 615 shares during the period. Aperio Group LLC increased its position in shares of bluebird bio by 9.7% during the second quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock worth $1,145,000 after acquiring an additional 646 shares during the period. Finally, Xact Kapitalforvaltning AB increased its position in shares of bluebird bio by 12.3% during the second quarter. Xact Kapitalforvaltning AB now owns 7,330 shares of the biotechnology company’s stock worth $1,150,000 after acquiring an additional 800 shares during the period. 98.26% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on BLUE shares. SunTrust Banks reaffirmed a “buy” rating and set a $223.00 target price on shares of bluebird bio in a research report on Friday, August 3rd. Cantor Fitzgerald set a $122.00 target price on shares of bluebird bio and gave the stock a “sell” rating in a research report on Wednesday, September 5th. ValuEngine raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. William Blair reaffirmed a “buy” rating on shares of bluebird bio in a research report on Wednesday, September 5th. Finally, BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, June 27th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $212.21.

Shares of BLUE stock opened at $122.14 on Friday. bluebird bio Inc has a 52-week low of $120.02 and a 52-week high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.30) by ($0.61). The business had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $10.68 million. bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The business’s quarterly revenue was down 53.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.73) earnings per share. On average, equities research analysts expect that bluebird bio Inc will post -10.85 earnings per share for the current year.

In related news, insider Jeffrey T. Walsh sold 21,500 shares of bluebird bio stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $152.02, for a total transaction of $3,268,430.00. Following the transaction, the insider now directly owns 56,995 shares of the company’s stock, valued at $8,664,379.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director James Mandell sold 1,000 shares of bluebird bio stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $150.77, for a total transaction of $150,770.00. Following the transaction, the director now directly owns 1,568 shares in the company, valued at $236,407.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,859 shares of company stock worth $10,029,606. 3.00% of the stock is currently owned by corporate insiders.

bluebird bio Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Read More: Penny Stocks

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply